However, it may be an effective adjunctive therapy for patients with AHA, especially those with high-titer FVIII inhibitors who are refractory to immunosuppressive therapy or for whom such therapy is contraindicated due to active infectious complications.12,13) PE can rapidly eliminate circulating FVIII inhibitors and facilitate hemostasis. This evidence concerns the gene F8 and autoimmune hemolytic anemia.